NASDAQ
TBPH
Last Price
US $16.92
KEY FIGURES
MKT CAP
$0.9B
EPS
TTM
$2.23
PEG
TTM
0.00x
P/E
TTM
7.57x
P/S
TTM
7.90x
YIELD
0.00%
GROWTH
Revenue Y/Y
8.38%
(FY vs FY)
EBITDA Y/Y
Cash Flow (DCF)
Fair Value
Market $16.92
—
Default assumptions
EBITDA Multiple
Fair Value
Market $16.92
-95.57%
Default assumptions
Valuation
Financial
Performance
Financial stability - Cash flow debt coverage.
Theravance Biopharma Inc cash flow to debt ratio of 315.96% indicates that the company generates enough cash to cover a substantial portion of its debt. This level indicates very strong financial health.
Financial stability - Healthy cash flow growth.
Theravance Biopharma Inc's free cash flow has increased -2.11K% from $-11.87M last year to $238.50M, signaling increasing performance
Financial stability - Healthy debt to equity ratio.
Theravance Biopharma Inc's debt to equity ratio is 0.25, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.
Financial stability - Healthy debt to equity ratio development.
Theravance Biopharma Inc's debt has decreased relative to shareholder equity from 0.28 last year to 0.25 today, signaling strengthened financials
Financial stability - Net debt/EBITDA.
Theravance Biopharma Inc has a net debt to EBITDA ratio of 0.00x, which is below the 3.00x threshold, indicating healthy leverage and financial stability
Financial risk - ICR.
Theravance Biopharma Inc's interest coverage ratio is 0.05, which means that the company struggles to meet interest obligations, signaling financial risk.
Financial stability - Profit margin growth.
Theravance Biopharma Inc's profit margin has increased (-219.07%) in the last year from -87.63% to 104.34%, signaling increasing performance
Financial stability - Short term assets vs short term liabilities.
Theravance Biopharma Inc's short-term assets of $418.46M exceed its short-term liabilities of $38.30M
Increasing performance - ROA.
Theravance Biopharma Inc's return on assets of 24.25% is higher than the 5.00% threshold, indicating efficient asset utilization
Increasing performance - Absolute return on equity.
Theravance Biopharma Inc's return on equity of 43.85%, is higher than 15.00%, indicating good performance
Increasing performance - Earnings quality.
Theravance Biopharma Inc's operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation
Decreasing performance - Earnings stability.
Theravance Biopharma Inc had positive net income in only 2.00 out of 5 years, indicating unstable earnings
Increasing performance - Free cash flow.
Theravance Biopharma Inc has positive free cash flow, indicating the company generates cash after capital expenditures
Increasing performance - FCF yield.
Theravance Biopharma Inc has a free cash flow yield of 27.20%, which is above the 2.00% threshold, indicating strong cash generation relative to market value
Increasing performance - Healthy earnings growth.
Theravance Biopharma Inc's yearly earnings has increased -287.70% since last year from $-56.42M to $105.89M, signaling increasing performance
Increasing performance - Healthy revenue growth.
Theravance Biopharma Inc's yearly revenue has increased 66.92% since last year from $64.38M to $107.46M, signaling increasing performance
Decreasing performance - ROIC.
ROIC 0.02% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.
Increasing performance - 3-year revenue CAGR.
Theravance Biopharma Inc's 3-year revenue CAGR of 27.91% is positive, indicating growing revenue over the past 3 years
Increasing performance - Revenue consistency.
Theravance Biopharma Inc had revenue growth in 3.00 out of 5 years, indicating consistent revenue performance
Decreasing performance - ROE consistency.
Theravance Biopharma Inc had positive ROE in only 2.00 out of 5 years, indicating inconsistent returns on equity
Overvalued - DCF valuation.
Theravance Biopharma Inc has insufficient data to evaluate this check.
Undervalued - Earnings yield.
Theravance Biopharma Inc has an earnings yield of 13.20%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings
Overvalued - EBITDA valuation.
Theravance Biopharma Inc is overvalued relative to its fair value price of 0.75 based on EBITDA multiple model
Undervalued - EV/EBITDA.
Theravance Biopharma Inc has an EV/EBITDA ratio of 5.72x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings
Undervalued - PEG ratio value.
Theravance Biopharma Inc has a PEG-ratio under 1 which is considered undervalued
Undervalued - P/B ratio.
Theravance Biopharma Inc has a price-to-book ratio of 2.99x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value
Undervalued - P/S ratio.
Theravance Biopharma Inc has a price-to-sales ratio of 7.90x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue
Profit margin
Current Ratio
Capital Returns
43.85%
Return on equity
ROIC: 0.02%
Valuation History
7.5X
Price to Earnings
EV/EBITDA: 4.7X
Cash flow
Profit margin
-
(FY vs FY)
Cash flow Y/Y
-
(FY vs FY)
EARNINGS FV (GRAHAM)
Fair Value
Market $16.92
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.